Date: 2012-05-23
Type of information: R&D agreement
Compound: antibody therapeutics targeting HER3 (HER3 belongs to the epidermal growth factor family which includes HER2 target of Herceptin® (Genentech/ Roche) and EGFR1 target of Erbitux® (Eli Lilly and Merck Serono). HER3 is over expressed in certain patient populations with gastric, head and neck, ovarian and breast cancers.)
Company: Immune Pharmaceuticals (Israel-USA) Yeda Research and Development Company (commercial arm of the Weizmann Institute of Science - Israel)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: Immune Pharmaceuticals, an emerging leader in the development of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, have announced a broad collaboration to develop antibody therapeutics targeting HER3. Immune Pharmaceuticalswill develop and evaluate multiple anti-HER3 antibody formats including humanized monoclonal antibodies, dual epitope targeting bi-specific antibodies and Antibody Nanoparticle Conjugates (NanomAbs).
Financial terms:
Latest news:
